|
Lithuania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Lithuania Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Lithuania.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Lithuanian pharmaceutical and healthcare industry.
Competitive intelligence, Lithuanian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Lithuanian market.
The Lithuania Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Lithuania Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Lithuanian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Lithuania to test other views – a key input for successful budgeting and strategic business planning in the Lithuanian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Lithuanian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lithuania.
- Exploit The Latest Competitive Lithuanian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Lithuania.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Lithuania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Lithuania Pharmaceuticals And Healthcare Industry SWOT |
| Political SWOT |
| Economic SWOT |
| Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
| Limits of Potential Returns |
| Risk to Realisation of Returns |
Chapter - Lithuania – Market Summary |
| Regulatory Regime |
| Regional Collaboration |
| Recent EU-Wide Regulatory Developments |
| Adherence Mandator |
| Intellectual Property Developments |
| Pricing Regime |
| Reimbursement Regime |
Chapter - Industry Developments |
| Epidemiology |
| Table: Selected Health Indicators For Lithuania, 1995-2004 |
| Healthcare System |
| Table: Healthcare Facilities And Personnel In Lithuania, 1995-2005 |
| Healthcare Funding |
| Healthcare Insurance |
| Corruption |
| Pharmaceutical Industry |
| Table: Drugmakers, Distributors And Retailers Active In The Baltic States, Q207 |
| Recent Pharmaceutical Industry Developments |
| Pharmaceutical Wholesale And Distribution |
| Pharmaceutical Retail |
| Biotechnology |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Lithuania - Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Lithuania - Healthcare Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Recession Ahead In 2009 |
| Table: Lithuania – Economic Activity |
| Prescription Market Forecast |
| Table: Lithuania - Prescription Market Indicators, Historical Data and Forecasts (LTLmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Lithuania – Patented Drug Market Indicators, Historical Data And Forecasts |
| Generics Market Forecast |
| Table: Lithuania – Generics Market Indicators, Historical Data And Forecasts |
| OTC Market Forecast |
| Table: Lithuania – OTC Market Indicators, Historical Data And Forecasts (LTLmn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Lithuania – Pharmaceutical Trade, Historical Data And Forecasts (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Lithuania - Other Healthcare Indicators, Historical Data And Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Multinational Company Profiles |
| GlaxoSmithKline |
| Pfizer |
| Novartis |
| Merck & Co |
| Sanofi-Aventis |
| Indigenous Company Profiles |
| Valentis |
| Sanitas |
| Sicor Biotech |
Chapter - Country Snapshot: Lithuania Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Lithuania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In the BMI‘s Business Environment Ranking matrix for Q209, Lithuania’s position has worsened from 11th to 13th out of the 20 main markets surveyed in Central and Eastern Europe (CEE) (which now include Moldova and Belarus). The change was due to a lower overall score, as the country struggles with economic downturn and slowdown in exports. Nevertheless, Lithuania’s pharmaceutical market is likely to experience a better compound annual growth rate (CAGR) than its Baltic neighbour Latvia. By 2013, the market will reach the valuation of LTL1.49bn (US$552mn), growing at a CAGR of 3.72% in local currency terms. This is a decrease from the 2008 level of LTL1.24bn (US$511mn).
While the government is likely to undertake significant reductions in public spending over the coming year, in January 2009 the local press reported that Lithuania will receive a funding of some EUR0.34mn (US$0.44mn) from Switzerland. This would be as part of an international cooperation agreement. A large part of the fund will be used for developing Lithuania's healthcare system, which includes the improvement of hospital infrastructure, healthcare services offered to pregnant women, and the development of fundamental science research.
On the company news front, there have been relatively few major developments. A new production facility in the city of Kaunas – which had been inaugurated in October 2008 by leading domestic pharmaceutical producer, Sanitas – was inspected by the State Medicines Control Agency in early 2009. The plant received a good manufacturing practice (GMP) certification, with Sanitas planning to diversify its product range and increase its export activities, given the limited opportunities in its home market.
In the meantime, pharmaceutical companies operating across the European Union (EU) (of which Lithuania is a member), the recent adoption of a proposal for harmonising the rules and procedures related to changing marketing authorisations should work towards facilitating of market access. The directive amendment would make all medicines – including those authorised through a national approval route – subject to a single set of legislation. This is a development welcomed by a number of European manufacturers’ associations. The proposal is part of a global revision of EU regulatory framework, which should minimise Bloc-wide variations in national rules, and also further encourage the use of the EU's mutual recognition process for the approval of initial marketing authorisations of medicines.
|
Lithuania Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |